文献速递临床试验与 GCP医学教育与科研方法

低血糖预防、症状识别与治疗(HypoPAST):完全在线心理教育项目用于成人1型糖尿病的24周混合1型随机对照试验方案

Hypoglycaemia Prevention, Awareness of Symptoms, and Treatment (HypoPAST): protocol for a 24-week hybrid type 1 randomised controlled trial of a fully online psycho-educational programme for adults with type 1 diabetes.
PubMed 文献 · Trials · 2024-10-29

本研究为24周、两组平行、混合1型随机对照试验,远程招募自报1型糖尿病且恐惧低血糖的澳大利亚成人,按1:1随机分配至HypoPAST或常规照护,主要结局为24周时低血糖恐惧(HFS-II担忧评分)的组间差异,需样本量196例以检测9分差异(90%把握度,允许30%脱落)。

要点

  • HypoPAST为完全在线、自我引导、可扩展的心理教育干预,旨在减少低血糖恐惧。
  • 主要结局为24周时HFS-II担忧评分的组间差异,样本量196例可检测9分差异。
  • 研究将评估HypoPAST的有效性、成本效果与可接受性。

核心结论

  • 本研究将提供HypoPAST这一新型在线心理教育项目有效性、成本效果与可接受性的证据。
  • 由于完全在线的形式,HypoPAST有望为减少成人1型糖尿病患者的低血糖恐惧提供低成本、便利、可及且可扩展的解决方案。

研究设计与样本

  • 24周、两组平行、混合1型随机对照试验,远程(在线与电话)开展。
  • 招募自报1型糖尿病且恐惧低血糖的澳大利亚成人(≥18岁),按1:1随机分配至HypoPAST组或对照组(常规照护)。
  • 样本量N=196,以90%把握度检测9分差异,并允许30%脱落。
  • 数据在基线、12周和24周通过在线调查、2周生态瞬时评估、网站分析和半结构化访谈收集。

关键数值与推荐

  • 主要结局为24周时低血糖恐惧(采用HFS-II担忧评分评估)的组间差异。
  • 样本量N=196可检测9分差异,把握度90%,允许30%脱落。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Management of type 1 diabetes (T1D) requires the use of insulin, which can cause hypoglycaemia (low blood glucose levels). While most hypoglycaemic episodes can be self-treated, all episodes can be sudden, inconvenient, challenging to prevent or manage, unpleasant and/or cause unwanted attention or embarrassment. Severe hypoglycaemic episodes, requiring assistance from others for recovery, are rare but potentially dangerous. Repeated exposure to hypoglycaemia can reduce classic warning symptoms ('awareness'), thereby increasing risk of severe episodes. Thus, fear of hypoglycaemia is common among adults with T1D and can have a negative impact on how they manage their diabetes, as well as on daily functioning, well-being and quality of life. While advances in glycaemic technologies and group-based psycho-educational programmes can reduce fear, frequency and impact of hypoglycaemia, they are not universally or freely available, nor do they fully resolve problematic hypoglycaemia or associated worries. This study aims to determine the effectiveness of a fully online, self-directed, scalable, psycho-educational intervention for reducing fear of hypoglycaemia: the Hypoglycaemia Prevention, Awareness of Symptoms, and Treatment (HypoPAST) programme. METHODS: A 24-week, two-arm, parallel-group, hybrid type 1 randomised controlled trial, conducted remotely (online and telephone). Australian adults (≥ 18 years) with self-reported T1D and fear of hypoglycaemia will be recruited, and allocated at random (1:1) to HypoPAST or control (usual care). The primary outcome is the between-group difference in fear of hypoglycaemia (assessed using HFS-II Worry score) at 24 weeks. A sample size of N = 196 is required to detect a 9-point difference, with 90% power and allowing for 30% attrition. Multiple secondary outcomes include self-reported psychological, behavioural, biomedical, health economic, and process evaluation data. Data will be collected at baseline, 12 and 24 weeks using online surveys, 2-week ecological momentary assessments, website analytics and semi-structured interviews. DISCUSSION: This study will provide evidence regarding the effectiveness, cost-effectiveness and acceptability of a novel, online psycho-educational programme: HypoPAST. Due to the fully online format, HypoPAST is expected to provide an inexpensive, convenient, accessible and scalable solution for reducing fear of hypoglycaemia among adults with T1D. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12623000894695 (21 August 2023).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Halliday JA, Holmes-Truscott E, Thuraisingam S, et al. Hypoglycaemia Prevention, Awareness of Symptoms, and Treatment (HypoPAST): protocol for a 24-week hybrid type 1 randomised controlled trial of a fully online psycho-educational programme for adults with type 1 diabetes. Trials. 2024. PMID: 39468682. doi:10.1186/s13063-024-08556-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。